Compare PubMatic Inc (PUBM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Repligen Corporation Common Stock — how do they compare? PubMatic Inc trades at $17.61 (market cap $802.59M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 14.1× PubMatic Inc's market cap, and PubMatic Inc is more actively traded (589,504 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Repligen Corporation Common Stock for 0 Days on average.
| PUBM | RGEN | |
|---|---|---|
Market Cap | $802.59M | $11.31B |
Volume | 589,504 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $19.18 | $194.57 |
52-Week Low | $6.28 | $102.87 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $705.72M | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUBM trades at $18.89, up 2.0% today, with a bullish technical setup and strong analyst consensus. Recent earnings beats and positive cash flow trends contrast with negative net income margins. The stock benefits from AI-driven ad tech growth and new leadership appointments, though it faces profitability challenges amid competitive pressures.
Outlook: Upside exists if profitability improves, supported by AI adoption and double-digit revenue growth in key segments. Risks include sustained losses, CFO transition, and ad market volatility. The consensus price target of $19.89 suggests modest near-term potential.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
